注射用复方维生素(4)的制备及质量考察

目的：制备注射用复方维生素（4）并考察其稳定性。方法：以含量、酸度为指标，筛选处方及制备工艺；并考察了3批样品的稳定性。结果：制剂最后处方为维生素A棕榈酸酯、维生素D2，维生素E，维生素K1加适宜的辅料制成，以该处方制备的3批样品在市售包装条件下经加速、室温留样试验考察，质量稳定。结论：处方设计合理，工艺可行。     

阿奇霉素分散片制备工艺研究

目的：优化阿奇霉素分散片制备工艺。方法：以片剂的硬度、溶出度、分散均匀度及外观为综合考察指标,建立了一个优化的处方工艺,并对其稳定性进行考察。结果：选用黏合剂浓度为6．0％（w/w）,黏合剂用量为45％（w/w）,配制乙醇浓度30％（w/w）,液体香精为1．3％（w/w）的处方,效果最佳。结论：该工艺研制的阿奇霉素分散片质量指标符合药典要求,生产工艺稳定。     

注射用富马酸伊布利特的制备及质量研究

目的：制备注射用富马酸伊布利特并建立其质量控制方法。方法：考察预冻溶液pH值，筛选赋形剂的种类和用量，得出最佳处方。建立了高效液相色谱法测定其含量及有关物质，并通过长期试验考察其稳定性。结果：预冻溶液最佳pH值为4．0—5．0；所采用的4种赋形剂中，甘露醇效果最优，其最佳用量为10．0％；含量测定中回收率为99．3％～100．1％（RSD〈1．0％）。注射用富马酸伊布利特的各项检测指标均达到质量标准的要求，经长期留样12个月质量稳定。结论：处方合理，制备工艺可行，产品质量可控。     

酒石酸美托洛尔骨架缓释片的制备及释放度测定

目的：制备酒石酸美托洛尔缓释骨架片。方法：采用亲水性高分子材料HPMC为骨架，制备酒石酸美托洛尔缓释片，采用正交试验法以药物体外释药百分率为指标优选制剂处方。结果：最佳处方为30％HPMC K4M作阻滞剂、淀粉和乳糖（1：1）为填充剂，10％PVP乙醇液为黏合剂，1％硬脂酸镁为润滑剂，采用湿法制粒，压片。结论：本品制备工艺简便，药物体外释放符合Higuchi模型，自制缓释骨架片较市售缓释片具有更好的缓释效果，能维持药物12h内缓慢释放。     

加替沙星滴眼液处方筛选及含量测定

目的：正交试验筛选加替沙星滴眼液的最佳处方．并建立其含量测定方法。方法：以黏度为考察指标．用正交试验考察羟丙甲纤维素（HPMC）型号、浓度、溶液pH对滴眼液黏度的影响，筛选最佳处方组成；采用高效液相色谱法（HPLC）测定加替沙星滴眼液中加替沙星的含量。结果：最佳处方组合为A3B1C3；HPLC线性关系良好。平均回收率为100．1％，RSD为1．2％。结论：该处方设计合理．含量测定方法能有效控制制剂质量。     

2008-01辅酶Q10亚微乳的制备及理化性质考察

目的：制备辅酶瓯亚微乳，并考察其稳定性及理化性质。方法：设计正交试验优选辅酶Q10亚微乳的处方及制备工艺并制备乳剂，以高效液相色谱法测定其含量及包封率，考察其粒径、ζ电位、pH值及稳定性等。结果：辅酶Q10亚微乳的最佳处方工艺为大豆油：中碳链甘油三酸酯＝1：2，大豆磷脂：泊洛沙姆188＝3：1，     

注射用氨酪酸的研制

目的研制注射用氨酪酸并建立其质量控制方法．考察其稳定性和安全性。方法拟订处方组成与制备工艺，进行性状、鉴别、pH值、有关物质检查等研究，采用非水滴定法测定氨酪酸含量，通过影响因素试验、加速试验和长期试验考察其稳定性，以其血管刺激性、溶血性及全身过敏性试验评价用药安全性。结果确定了不加赋形剂的处方，以及将氨酪酸直接冻干的工艺；影响因素试验（10d）、恒温加速试验（6个月）和长期留样试验（24个月）表明。主药含量及其他氨基酸无明显改变。结论处方工艺合理可行，制剂质量可控、稳定性良好、安全。     

降糖通脉无糖型颗粒制备工艺研究

目的优选降糖通脉无糖型颗粒的制备工艺。方法采用L9（3^4）正交试验，考察赤芍等药材的煎煮条件，以干膏收率和芍药苷含量双指标进行工艺筛选，对结果以综合评分法进行计算；通过颗粒成型性试验考察辅料及处方量。结果确定的煎煮条件为加8倍量水煎煮3次，每次1．5h；辅料选择75％乙醇，干膏量一可溶性淀粉（1：1）。结论该制备工艺可行。     

乙二胺四醋酸钠铁口服液的制备及稳定性

目的：制备乙二胺四醋酸钠铁口服液，建立其质量控制方法，并进行稳定性考察。方法：以乙二胺四醋酸钠铁为主药制备口服液，采用紫外-可见分光光度法测定含量，并考察制剂的加速及长期稳定性。结果：本品中铁的含量在1.0～4.6mg·L^-1的范围内呈良好的线性关系，r=0．9999（n=5）。市售包装下在温度（40±2）℃和相对湿度（75±5）％条件下保存，6个月内稳定；在温度（25±2）℃和相对湿度（60±10）%条件下保存，12个月内稳定。结论：该制剂处方合理，制备工艺简单，含量测定方法简便，制剂稳定性良好，值得推广使用。     

米格列奈钙缓释片制备工艺与体外释放度研究

目的：确定米格列奈钙缓释片最佳制备工艺并对其体外释放度进行考察。方法：采用单因素考察、正交试验设计,确定米格列奈钙缓释片最佳制备工艺,并照《中国药典））2010年版（二部）释放度测定法测定其体外释放度。结果：米格列奈钙缓释片处方：米格列奈钙5．0g,羟丙基甲基纤维素（HPMC,K15M）30．0g,乳糖80．0g,3％聚维酮（VW）水溶液适量,硬脂酸镁2．0g;最佳制备工艺：将上述原辅料过120目筛,充分干燥,按处方量称量、混匀,用3％PVP水溶液作为黏合剂制成软材,40目筛制粒,50℃干燥;40目筛整粒,加润滑剂混匀,测含量;用φ7．0mm圆形浅弧冲压片（8kg／cm2）,每片重120mg;米格列奈钙缓释片体外释放度符合良好的Higuchi方程（r=0．9983）。结论：本研究制备的米格列奈钙缓释片具有良好的缓释效果。     

吲哚美辛肠溶片处方工艺对释放度的影响

通过对吲哚美辛肠溶片处方及工艺的改进，如添加适量乳糖和十二烷基硫酸钠及PVP、控制原药细度、修改包衣工艺等措施，解决了原产品存在的释放度低及其在贮存期间释放下降的问题，使吲哚美辛肠溶片释放工增加，稳定性提高。     

Effect of processing and formulation variables on the stability of a salt of a weakly basic drug candidate

The effect of some processing and formulation variables on the stability of tablets containing a crystalline salt of a triazine derivative was studied. The salt has a relatively low melting point and a low microenvironmental pH due to the weakly basic nature of the parent compound (pKa = 4.0). This compound decomposes through acid-catalyzed hydrolysis. A full factorial design was used to study the effect of three variables on tablet stability: aqueous wet granulation, ball milling of the salt and filler prior to manufacturing, and the inclusion of sodium carbonate in the formulation as a pH modifier. In addition to the factorial design experiments, a batch of tablets was prepared by wet granulation, using sodium bicarbonate as the pH modifier. Stability of the drug in tablets was evaluated at 40 degrees C/75% relative humidity (RH) and at 40 degrees C/ambient humidity. Stability of tablets was adversely affected by wet granulation. However, stability was greatly improved by wet granulation in the presence of sodium carbonate. While sodium carbonate enhanced drug stability in the tablets, regardless of the manufacturing process, wet granulated tablets were more stable than tablets containing sodium carbonate and prepared without wet granulation. Similarly prepared tablets by using sodium bicarbonate were remarkably less stable compared with those containing sodium carbonate. The use of sodium bicarbonate as a pH modifier resulted in only marginal enhancement of tablet stability, suggesting that a higher microenvironmental pH than that provided by sodium bicarbonate is needed to maximize stability. Despite the low lattice energy of the salt and the potential for disruption of salt crystallinity by mechanical stress, milling did not appear to have an adverse effect on tablet stability under the current experimental conditions. This study shows that selection of the proper manufacturing process, in conjunction with the appropriate pH modifier, could be critical to dosage form stability.     

Effect of binders on sulfamethoxazole tablets

Five batches of sulfamethoxazole tablets were prepared using different binders [starch, acacia, ethyl cellulose sodium carboxymethylcellulose, and povidone (1-vinyl-2-pyrolidinone polymer, PVP)] with water in 3% (dry basis) concentration. Comparative data show that granules prepared with PVP have the best flow properties and minimum angle of repose, percentage fines, and compressibility, while granules of sodium carboxymethylcellulose could not be compressed into well-defined tablets. Tablets containing starch as a binder possess all the quality features. Tablets from acacia, however, give a poor dissolution profile. Ethyl cellulose has less effective granule formation, leading to poor quality tablets. Rank correlation with respect to solubility and absorption characteristics according to granulating agent in the formation is: starch greater than ethyl cellulose greater than PVP greater than acacia.     

Preparation and in vitro evaluation of enteric-coated tablets of rosiglitazone sodium

The aim of this study was to prepare the rosiglitazone sodium enteric-coated tablets and investigate its release rate. The rosiglitazone sodium enteric-coated tablet was prepared by single punch tablet press using substituted hydroxypropyl cellulose and polyvinylpyrrolidone (PVP). The release rate from the enteric-coated tablet of rosiglitazone sodium was evaluated. The release rate study showed that few rosiglitazone sodium was released from enteric coated formulation within 2 h in simulated gastric juice, while it released more than 80% of the labeled amount in 30 min in simulated intestinal juice. The preparing method of rosiglitazone sodium enteric-coated tablets was simple and had a good reproducibility. The release condition and determined methods could be used for the routine determinations of rosiglitazone sodium enteric-coated tablets.     

Preparation and <Emphasis Type="Italic">in vitro</Emphasis> evaluation of povidone-sodium cholate-phospholipid mixed micelles for the solubilization of poorly soluble drugs

Mixed micelles made of polyvinylpyrrolidone (PVP), sodium cholate, and phospholipids were prepared to improve the solubility of poorly water-soluble drugs. Sylibin, a drug used in treating liver diseases, was incorporated into the mixed micelles. The formulation of sylibin containing PVP-sodium cholate-phospholipid mixed micelles with an optimized composition (PVP/sodium cholate/phospholipid/silybin = 3:3:4:1∼2 by weight) was obtained based on the study of pseudoternary phase diagrams. The critical micelle concentration was used to evaluate the micellar stability towards dilution. The results showed that addition of PVP to sodium-cholate-phospholipid mixed micelles increased stability. The solubility of sylibin in PVP-sodium cholate-phospholipid mixed micelles was higher than that in pure water or in sodium cholate-phospholipid mixed micelles. In a stability study, we found that PVP-sodium cholate-phospholipid mixed micelles showed good stability. After 3 months storage at 40°C, just 2.6% sylibin was lost with only minor changes of the particle size when compared to a reference formulation containing sodium cholate and phospholipid mixed micelles. In addition, the developed formulation significantly improved in vitro drug release. The time required to release 50% sylibin (t50%) from sodium cholate and phospholipid mixed micelles was 326 h, while the t50% from PVP-sodium cholate-phospholipid mixed micelles was only 51.1 h. Our results suggest that these mixed micelles might have significant potential application to the biomedical field.     

无时滞非达霉素肠溶片的制备及溶出评价

目的: 制备无时滞非达霉素肠溶片,考察其溶出特性。方法: 采用湿法制粒工艺,通过正交实验进行片芯优化,以甲基丙烯酸与丙烯酸乙酯共聚物为肠溶包衣材料,制备非达霉素肠溶片,以体外释放度为指标,考察其溶出行为。结果: 片芯中羟丙甲纤维素和交联羧甲基纤维素钠的用量分别为1.2%和4.5%,微晶纤维素和淀粉的比例为3:1,肠溶层共聚物的比例为50%时,制备的非达霉素肠溶片在pH1.0盐酸中2h释放度小于10%,在pH4.5醋酸盐缓冲液中可以崩解释放,在pH6.8磷酸盐缓冲液中快速释放,10min释放度大于60%。结论: 制备的非达霉素肠溶片与普通肠溶片相比无时滞效应,有望进行工业化生产。     

硫酸沙丁胺醇延迟释药片的制备及质量控制

目的:制备硫酸沙丁胺醇延迟释药片,并建立其质量控制方法。方法:用硫酸沙丁胺醇、乳糖、羧甲基淀粉钠、羟丙基甲基纤维素、乙基纤维素、微晶纤维素制备成缓释片,再用肠溶型丙烯酸树脂包衣,制备成延迟释药片;采用高效液相色谱法测定该延迟释药片中硫酸沙丁胺醇的含量,同时对其体外释放度进行测试,并考察其稳定性。结果:硫酸沙丁胺醇检测浓度在1.25～20.00μg/ml范围内与吸收峰面积积分值线性关系良好;平均回收率为98.60%(RSD=0.66%);制备的延迟释药片在服用后约5h定时释药,且在各项稳定性试验中,释放度均无明显变化。结论:本制剂组方合理,制备工艺简便可行,质量稳定可控。     

复方替米沙坦片的制备及其稳定性研究

目的:制备复方替米沙坦片并对其稳定性进行考察.方法:制备替米沙坦分散体以提高替米沙坦的水溶性,选用利于氢氯噻嗪稳定的辅料,采用双层压片工艺制备了复方替米沙坦片,对处方工艺进行筛选与优化,采用高效液相色谱法测定其含量,并通过加速试验考察片剂稳定性.结果:以优选处方工艺制备的样品质量稳定,高效液相色谱法测定该片替米沙坦和氢氯噻嗪含量的平均回收率分别为99.85%(RSD=0.79%)和99.37%(RSD=0.40%).结论:该处方工艺合理,所得产品质量稳定.     

HPLC法测定左旋泮托拉唑钠肠溶微丸的含量和有关物质

目的测定左旋泮托拉唑钠肠溶微丸胶囊的含量和有关物质。方法建立HPLC法,色谱柱:DiamonsilTMC18(5μm,4.6 mm×250 mm),流动相:乙腈-磷酸盐缓冲液(取磷酸氢二钠1.12 g,磷酸二氢钠0.18 g,加水溶解并稀释至1 000 mL,调pH值至7.6)(体积比为30∶70),检测波长:288 nm。结果左旋泮托拉唑在20.0~100.0 mg.L-1内线性关系良好,r=0.999 6,平均回收率为99.3%(n=9),RSD%=0.54。结论方法可用于制剂的含量和有关物质测定。     

伏立康唑片的制备及其质量评价

目的制备并评价伏立康唑片。方法采用预胶化淀粉、一水乳糖、交联羧甲基纤维素钠、聚维酮、硬脂酸镁制备伏立康唑片,并对其进行薄膜包衣。采用正交设计法确定最佳处方。对其硬度、脆碎度和溶出度进行考察并与市售伏立康唑片比较。结果预胶化淀粉、一水乳糖、交联羧甲基纤维素钠、硬脂酸镁的用量分别为片重的40%,21%,3%和1%,采用5%聚维酮K90水溶液做黏合剂,片芯硬度为15 kg.cm 2,包衣厚度为4%左右时,伏立康唑片的溶出度接近原研产品。结论伏立康唑片的制备工艺简单,重现性好,药物的溶出行为达到预期目的。